LOB International

LOB International is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 1978, the company is headquartered in Mumbai, Maharashtra, at G-6 Khira Industrial Estate, B. M. Bhargav Road, Santacruz West. The firm operates as both an importer and exporter, facilitating bidirectional trade across key categories such as pharmaceutical products, medical supplies, and consumer goods. The company's website is www.lobin.com.

LOB International's ownership structure is not publicly disclosed. The company employs a small team, with an estimated workforce of 1-10 employees. Specific financial details, including annual revenue, are not publicly available. The company's operations encompass a diverse product portfolio, including toiletries, confectionery, non-alcoholic beverages, and various consumer goods.

LOB International does not own manufacturing facilities; instead, it operates as a trading company, sourcing products from various manufacturers. The company specializes in exporting finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the manufacturing capacities and specializations of its suppliers are not publicly disclosed.

The key leadership of LOB International includes Mr. Val Lobo, who serves as the Chief Executive Officer (CEO). Specific details regarding other executive roles, such as Chief Financial Officer (CFO) or other key executives, are not publicly available. The company's leadership is focused on facilitating international trade and ensuring the quality of the pharmaceutical products it exports.

LOB International's export data indicates a significant presence in regulated markets, with a total export value of $460,000 USD across 99 shipments from 2022 to 2026. The company's product portfolio includes three pharmaceutical products across three therapeutic categories. The top three products exported are Praziquantel, Linagliptin, and Betadine, with Praziquantel being the leading product with a market share of 13.7%. The therapeutic categories include Antimalarial & Antiparasitic (86.9%), Advanced Diabetes Medications (10.6%), and Brand Names & OTC Products (2.5%). LOB International holds the #1 market leader position in Praziquantel. The company's portfolio is highly concentrated, with the top five products accounting for 100% of its exports.

LOB International's export data does not provide specific information regarding its presence in emerging markets such as Africa, Latin America, or Southeast Asia. The company's focus appears to be on regulated markets, as indicated by its export data. Specific details about WHO prequalification or other certifications enabling access to these markets are not publicly available.

LOB International's export data reveals a high concentration in a single product, Praziquantel, which accounts for 86.9% of its exports. This indicates a significant concentration risk, as the company's revenue is heavily dependent on the success of this product. The strategic direction appears to be focused on exporting a limited range of products, primarily in the Antimalarial & Antiparasitic category. Diversification into other therapeutic areas or products could potentially mitigate this risk and enhance the company's market stability.

Specific details regarding LOB International's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history are not publicly available. As a trading company, LOB International may not hold direct FDA approvals but could source products from manufacturers with FDA-approved facilities. However, without explicit information, it is challenging to assess the company's compliance status with the U.S. Food and Drug Administration.

LOB International's export data does not provide information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. As a trading company, LOB International may source products from manufacturers holding these certifications, but specific details are not publicly disclosed. The absence of this information makes it difficult to evaluate the company's adherence to international quality standards.

Specific details regarding LOB International's compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly available. As a trading company, LOB International may operate under the regulatory framework applicable to importers and exporters in India, but explicit information is not disclosed. The lack of publicly available regulatory compliance details necessitates further due diligence for potential partners.

There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts associated with LOB International. The company's export data does not indicate any regulatory actions or compliance issues in the markets it serves. However, the absence of detailed regulatory compliance information suggests that potential partners should conduct thorough due diligence to ensure adherence to applicable regulations.

LOB International operates in the competitive pharmaceutical export market, with major players such as Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Lupin Limited, and Dr. Reddy's Laboratories Limited. These companies have established significant market shares and global reach. LOB International's focus on a limited product portfolio, particularly in the Antimalarial & Antiparasitic category, positions it in a niche segment. While this specialization may reduce direct competition, it also limits the company's ability to leverage economies of scale and diversify its market presence.

LOB International's key differentiator lies in its specialization in exporting Praziquantel, a leading Antimalarial & Antiparasitic product, where it holds a 13.7% market share. This focus allows the company to develop expertise and establish strong relationships within this therapeutic area. However, the company's portfolio concentration on a single product may limit its ability to adapt to changing market demands and diversify its revenue streams.

LOB International's current strategic direction appears to be focused on exporting a limited range of products, primarily in the Antimalarial & Antiparasitic category. This specialization may offer advantages in terms of expertise and market positioning within this niche segment. However, the company's heavy reliance on a single product poses concentration risks. Exploring diversification into other therapeutic areas or expanding its product portfolio could enhance the company's resilience and growth prospects in the global pharmaceutical market.

As a trading company, LOB International sources its pharmaceutical products from various manufacturers. The company's export data indicates a total export value of $460,000 USD across 99 shipments from 2022 to 2026, with a portfolio concentration on three products. Specific details regarding the reliability, quality standards, and compliance of its suppliers are not publicly disclosed. Potential partners should conduct thorough due diligence to assess the consistency and quality of the products supplied by LOB International.

Importers considering partnerships with LOB International should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Approval: Confirm that the products are manufactured in facilities registered with the U.S. Food and Drug Administration.

• WHO-GMP Certification: Ensure that the manufacturing facilities adhere to the World Health Organization's Good Manufacturing Practices.

• EU GMP Certification: Verify that the products comply with the European Union's Good Manufacturing Practices.

• ISO Certification: Check for relevant International Organization for Standardization certifications that indicate quality management systems.

To verify these certifications, importers should request copies of the certificates from LOB International and cross-reference them with the issuing authorities' official records.

Importers should undertake the following steps to ensure a comprehensive evaluation of LOB International:

• Verify Supplier Certifications: Confirm that the manufacturing facilities hold valid FDA, WHO-GMP, EU GMP, and ISO certifications.

• Assess Product Quality